Cancer NetworkOriginal article
<![CDATA[Talazoparib/Enzalutamide sNDA Receives FDA Priority Review in HRR+ CSPC]]>
NDA FilingTalazoparibEnzalutamidePositive
AI Analysis
Summary
A supplemental NDA for talazoparib combined with enzalutamide received FDA Priority Review for treating HRR-altered metastatic castration-resistant prostate cancer, supported by positive TALAPRO-3 trial findings.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
sNDA received FDA Priority Review
Importance:7/10
Sentiment:
0.70
FDAPriority ReviewsNDAProstate CancerHRR-alteredTALAPRO-3Combination Therapy
Related Companies
Read the original article
Published by Cancer Network on July 23, 2026 4:00 PM